Inequalities in non-small cell lung cancer treatment and mortality

被引:26
|
作者
Nur, Ula [1 ]
Quaresma, Manuela [1 ]
De Stavola, Bianca [2 ]
Peake, Michael [3 ]
Rachet, Bernard [1 ]
机构
[1] London Sch Hyg & Trop Med, CRUK Canc Survival Grp, Dept Noncommuniicable Dis Epidemiol, London WC1E 7HT, England
[2] London Sch Hyg & Trop Med, Dept Med Stat, London WC1E 7HT, England
[3] Publ Hlth England, Natl Canc Intelligence Network, London, England
关键词
FUNNEL PLOTS; SURVIVAL; MANAGEMENT; RESECTION; ENGLAND; ACCESS; SURGERY; MODELS; BREAST; RATES;
D O I
10.1136/jech-2014-205309
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases, and surgery is the preferred treatment for patients. The National Health Service established Primary Care Trusts (PCTs) in 2002 to manage local health needs. We investigate whether PCTs with a lower uptake of surgical treatment are those with above-average mortality 1 year after diagnosis. The applied methods can be used to monitor the performance of any administrative bodies responsible for the management of patients with cancer. Methods All adults diagnosed with NSCLC lung cancer during 1998-2006 in England were identified. We fitted mixed effect logistic models to predict surgical treatment within 6 months after diagnosis, and mortality within 1 year of diagnosis. Results Around 10% of the NCSLC patients received curative surgery. Older deprived patients and those who did not receive surgery had much higher odds of death 1 year after being diagnosed with cancer. In total, 69% of the PCTs were below the lower control limit of surgery and have predicted random intercepts above the mean value of zero of the random effect for mortality, whereas 40% were above the upper control limit of mortality within 1 year. Conclusions Our main results suggest the presence of clear geographical variation in the use of surgical treatment of NSCLC and mortality. Mixed-effects models combined with the funnel plot approach were useful for assessing the performance of PCTs that were above average in mortality and below average in surgery.
引用
收藏
页码:985 / 992
页数:8
相关论文
共 50 条
  • [1] Treatment of non-small cell lung cancer
    Reinmuth, N.
    Heigener, D.
    Reck, M.
    INTERNIST, 2011, 52 (12): : 1414 - 1421
  • [2] Racial disparities in staging, treatment, and mortality in non-small cell lung cancer
    Duncan, Francesca C.
    Al Nasrallah, Nawar
    Nephew, Lauren
    Han, Yan
    Killion, Andrew
    Liu, Hao
    Al-Hader, Ahmad
    Sears, Catherine R.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (01) : 76 - 104
  • [3] Influenza and mortality for non-small cell lung cancer.
    Kinslow, Connor J.
    Wang, Yuankun
    Liu, Yi
    Zuev, Konstantin M.
    Wang, Tony J. C.
    Donalek, Ciro M.
    Amori, Michael
    Cheng, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Inequalities in outcomes for non-small cell lung cancer: the role of the MDT
    Beckett, Paul
    Woolhouse, Ian
    THORAX, 2012, 67 (10)
  • [5] Diagnosis and treatment of lung cancer - Non-small cell lung cancer, small cell lung cancer and carcinoids
    End A.
    European Surgery, 2006, 38 (1) : 45 - 53
  • [6] Morbidity and mortality following radical radiotherapy treatment for non-small cell lung cancer
    Abdelhalim, M. A.
    Maclay, J.
    Young, A.
    Barton, C.
    Lumsden, G.
    O'Rourke, N.
    MacGregor, G.
    LUNG CANCER, 2014, 83 : S57 - S57
  • [7] The Effect of Socioeconomic Status on Treatment and Mortality in Non-Small Cell Lung Cancer Patients
    Ebner, Peggy J.
    Ding, Li
    Kim, Anthony W.
    Atay, Scott M.
    Yao, Mimi J.
    Toubat, Omar
    McFadden, P. Michael
    Balekian, Alex A.
    David, Elizabeth A.
    ANNALS OF THORACIC SURGERY, 2020, 109 (01): : 225 - 232
  • [8] On the pharmacogenetics of non-small cell lung cancer treatment
    Santarpia, Mariacarmela
    Rolfo, Christian
    Peters, G. J.
    Leon, Leticia G.
    Giovannetti, Elisa
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 307 - 317
  • [9] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409
  • [10] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396